emphasis is mine.... but, the "traps" have been "when hell freezes over" stuff thus far.......
Thursday January 6, 4:50 pm Eastern Time
Company Press Release
Regeneron Names Stahl Vice President, Preclinical
Development and Biomolecular Science
TARRYTOWN, N.Y.--(BUSINESS WIRE)--January 6, 2000--Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN -
news) has promoted Neil Stahl, Ph.D., to Vice President, Preclinical Development and Biomolecular Science, a new position.
Dr. Stahl obtained his B.S. from Duke University and his Ph.D. in biochemistry from Brandeis University. Since joining
Regeneron in 1991, he has held a number of senior research positions. In 1997, he was appointed Vice President,
Biomolecular Science with responsibility for research and development of cytokine agonists and antagonists (including cytokine
traps) and Regeneron's small molecule discovery programs. In his new position, Dr. Stahl will have responsibility for preclinical
development activities required to initiate human clinical trials, including preclinical pharmacology, pharmacokinetics, toxicology,
formulation, and process development. Dr. Stahl will report to George D. Yancopoulos, M.D., Ph.D., Senior Vice President,
Research and Chief Scientific Officer of Regeneron.
Regeneron's current preclinical development programs include several cytokine antagonists (including an interleukin-1 trap for
rheumatoid arthritis, and interleukin-4 and interleukin-4/13 traps for asthma and allergic disorders), an antagonist for vascular
endothelial growth factor (VEGF) for cancer, and second generation AXOKINE® ciliary neurotrophic factor for obesity.
''Regeneron is delighted that Neil is taking on responsibility for preclinical development,'' commented Dr. Yancopoulos. ''He is
one of our most outstanding scientists and research managers and his promotion demonstrates our commitment to expeditiously
moving our scientific breakthroughs from the lab into the clinic. With a growing number of product candidates in our pipeline, as
well as an increasing number of people involved in preclinical development, Neil's skills are well matched to Regeneron's needs.
He brings a terrific combination of scientific talent and the ability to work with and motivate people.''
Regeneron is a leader in the application of molecular and cell biology to the search for novel human therapeutics. Regeneron
uses its expertise in growth factors and their mechanisms of action to discover and develop protein-based and small molecule
drugs. Regeneron is currently conducting a clinical trial of AXOKINE for the treatment of obesity and complications of obesity
such as Type II diabetes. Regeneron is also conducting clinical trials, in partnership with Amgen Inc., of brain-derived
neurotrophic factor (BDNF) for the treatment of amyotrophic lateral sclerosis and of neurotrophin-3 (NT-3) for the treatment
of constipation associated with spinal cord injury and other medical conditions. The Company has a number of research
collaborations, including a broad-based, long-term agreement with The Procter & Gamble Company.
This news release discusses historical information and includes forward looking statements about Regeneron's products,
programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with
preclinical and clinical development of drugs and biologics, determinations by regulatory and administrative governmental
authorities, competitive factors, technological developments, the availability and cost of capital, the costs of developing,
producing, and selling products, the potential for any collaboration agreement to be canceled or to terminate without any
product success, and other material risks. A more complete description of these risks can be found in Regeneron's Form 10-K
for the year ended December 31, 1998, and current Form 10-Q, copies of which should be read before making any
investment decision regarding Regeneron common stock.
Additional information about Regeneron and recent news releases are available on Regeneron's Worldwide Web Home Page
at www.regeneron.com. Fax copies of news releases can be obtained from Regeneron's News-on-Demand Service by dialing
(800) 311-0841.
Contact:
Regeneron Pharmaceuticals, Inc.
Murray A. Goldberg,
Vice President Finance and Administration and CFO
(914) 345-7492
or
Robinson Lerer & Montgomery
Michael Gross, Partner
(212) 484-7721 |
